Chronic lymphocytic leukemia (CLL), is a type of cancer that affects a type of white blood cell in your body called a lymphocyte. White blood cells are made in your bone marrow and help your body ...

Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) are types of slow-growing cancers that affect a type of white blood cell called a lymphocyte. Lymphocytes are cells that help ...

After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic ...

There have been major treatment advancements for CLL in the last decade, with future generations of drugs on the horizon. When it comes to the treatment of chronic lymphocytic leukemia, or CLL, there ...

Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...

Regimen offers another option for the potential of time off treatment, marking a meaningful advance in long-term disease management NORTH CHICAGO, Ill., Feb. 20, 2026 /PRNewswire/ -- AbbVie (NYSE: ...

Expert Rev Hematol. 2013;6(4):441-449. The newest biological variables of prognostic relevance are useful for understanding the clinical heterogeneity of disease, however, their value at the time of ...

Current and emerging treatments for relapsed or refractory CLL show promise, with outcomes expected to improve beyond current data. Treatment responses in CLL can last for years, especially in ...

A retrospective observational study of rapid titration of venetoclax (VEN) in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). This is an ASCO Meeting Abstract from the ...

First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY trial Regimen offers another option for the ...